Charité – University Medicine Berlin

Dept. of Pediatric Oncology, Hematology and BMT

Name of PI: Prof. Johannes H. Schulte

Charité – Universitätsmedizin Berlin
Dept. of Pediatric Oncology, Hematology and BMT
Company address: Augustenburger Platz 1
13353 Berlin

Team members working on ITCC-P4 with their position and email address
Company presentation

The Charité is one of the largest university hospitals in Europe. Here, 3700 doctors and scientists treat patients, do research and teach at the top international level. The Charité extends over four campuses with almost 100 clinics and institutes bundled under 17 Charité Centers. The strengths of Charité are patient-oriented research and the interconnection of state of the art medical care with basic and clinical research, teaching, and support for early-career clinicians and scientists. Additionally, the Charité is one of the two founding members of the newly established Berlin Institute of Health (BIH), in which the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and the Charité – Universitätsmedizin Berlin have joined forces. The core idea is to combine translational research with an overarching systems medicine approach to bridge the gap between basic research and clinical application.
The Dept. of Pediatric Oncology and Hematology, headed by Prof. Angelika Eggert, is one of the largest Pediatric Oncology Centers in Germany with approx. 150 newly diagnosed pediatric cancer patients per year. Major research focus is the field of embryonal pediatric tumors including neuroblastoma (NB), retinoblastoma (RB), and medulloblastoma (MB). Molecular biology and genetics research is focussed on genomic, transcriptomic, proteomic and epigenomic profiling of pediatric tumors and cell culture models. An additional major interest are xenograft and transgenic mouse models of embryonal tumors. The Dept. of Pediatric Oncology and Hematology further serves as the national study center for many clinical trials, e.g. childhood ALL and from 2021 for the new high-risk neuroblastoma trial HR-NBL2/SIOPEN. The department has a long-standing track record in different national (ENGINE, SMOOSE, SYSMED, TERMINATE-NB) and international research consortia (ENCCA, ASSET, OPTIMIZE-NB, ONTHETRRAC), currently with the coordinating role in the translational oncology collaborative research consortium ENABLE funded by the German Cancer Aid.